News

The drug was tested in the Clareos-1 and Clareos-2 trials, which featured over 1,500 patients, aged nine years and older with moderate-to-severe acne vulgaris. Olumacostat glasaretil was evaluated

Per the Prescription Drug User Fee Act, the target action date is October 20, 2018. Dupixent is a human monoclonal antibody specifically designed to inhibit signaling of interleukin-4

Mylan anticipates introducing Symfi Lo in the coming weeks and Cimduo in the second quarter of this year. These upcoming launches will extend Mylan's global antiretroviral (ARV) platform

The European Medicines Agency (EMA) has started an Article 20 referral procedure after reports of inflammatory encephalitis and meningoencephalitis. Seven cases of serious inflammatory brain disorders including encephalitis and meningoencephalitis

This is a result of the company’s 2025 strategy which increases the focus on new innovative solutions for medical dermatology and no longer pursue over-the-counter (OTC) in most

In just under nine months, the Company has now raised over $220 million. Rubius has developed the technology to grow, genetically engineer and mature long-circulating Red-Cell Therapeutics (RCT)

The injunction was obtained by Endo’s subsidiaries Par Pharmaceutical and Par Sterile Products (Par) from US District Judge Brian Martinotti. The order will prevent QuVa Pharma from marketing

BOTOX is the market-leading neuromodulator approved for the treatment of multiple indications and usage in the United States with additional approvals globally.  The addition of this product further

Under the terms of the agreement, GSK will use Covance Xcellerate® Monitoring, Xcellerate Insights, and Xcellerate Clinical Data Hub solutions in a software-as-a-service (SaaS) model. Covance technology products